Unified Program for Therapeutics in Children (UPTiC)

儿童治疗统一计划 (UPTiC)

基本信息

  • 批准号:
    10159122
  • 负责人:
  • 金额:
    $ 50.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

The development pipeline for prophylactics and therapeutics that target pediatric diseases is sparse compared to that of adults. A gap in the understanding of pediatric physician-scientists regarding how to span this translational divide compromises the development of promising therapies. The primary goal of this Unified Program for Therapeutics in Children (UPTiC) is to train young pediatric physician-scientists with strong academic potential to lead the development of novel therapeutics and prophylactics for children and be thought- leaders in the field of pediatric drug development. The program will train subspecialty pediatric fellows in 3 tracks that span the full pipeline of clinical development: 1) discovery-based research (preclinical/translational pediatric drug development), 2) clinical pediatric trials, and 3) outcomes/real world evidence. The program will cover three major training aims, including: 1) individualized didactic and degree-oriented course work in pediatric drug development, 2) mentored training in preclinical, clinical trials, and outcomes research, and 3) grant-writing training and mock review. The training of these pediatric research fellows will be through a combined effort bringing together the Duke University School of Medicine, including the Department of Pediatrics and the Duke Clinical Research Institute, and the University of North Carolina at Chapel Hill, including the Department of Pediatrics, School of Pharmacy, and School of Public Health. UPTiC will be led by a team of multi- university, multi-disciplinary, well-funded, and experienced faculty members, including 39 full-time Duke and UNC faculty members in Pediatrics and other basic, translational, and clinical science departments. This application requests support for six postdoctoral pediatric trainees (three new fellows per year, 2 years of support each). Trainees will be nationally recruited through established pediatric clinical trials networks led by the Duke Clinical Research Institute and Duke/UNC pediatric fellowship program directors and subsequently drawn from the pool of pediatric fellows at Duke and UNC. Individuals appointed to the training program will be named Katz- Denny Fellows. The training will center on research ongoing in the various faculty members' research groups across the Duke Medical Center and the University of North Carolina and a joint didactic program focusing on the therapeutic development pipeline for children. Upon completion of this training program, these pediatrician- scientists will be capable of not only leading translational and clinical pediatric-focused therapeutic development research, but also mentoring the next generation of pediatricians in the fundamentals of pediatric clinically- oriented research. Fulfillment of the program's objective would directly or indirectly address two imperatives: 1) the need for more full-time academic pediatric physician-researchers and mentors in medical schools throughout the country and 2) the unmet need for innovations and clinical translation of novel pediatric prevention and treatment strategies to improve the health of the youngest and most vulnerable members of our society.
相比之下,针对儿科疾病的预防和治疗药物的开发渠道很少

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian J Davis其他文献

Linking germline and somatic variation in Ewing sarcoma
尤因肉瘤中种系和体细胞变异的联系
  • DOI:
    10.1038/ng.3387
  • 发表时间:
    2015-08-27
  • 期刊:
  • 影响因子:
    29.000
  • 作者:
    Nicholas C Gomez;Ian J Davis
  • 通讯作者:
    Ian J Davis

Ian J Davis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian J Davis', 18)}}的其他基金

Developmental control of chromatin states in cancer
癌症中染色质状态的发育控制
  • 批准号:
    10567242
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10211263
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10580496
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10381604
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a cavitation enhancement technology to access archived tissues for epigenetic-based biomedical research
开发空化增强技术以获取存档组织以进行基于表观遗传学的生物医学研究
  • 批准号:
    10576937
  • 财政年份:
    2021
  • 资助金额:
    $ 50.71万
  • 项目类别:
Unified Program for Therapeutics in Children (UPTiC)
儿童治疗统一计划 (UPTiC)
  • 批准号:
    10400848
  • 财政年份:
    2019
  • 资助金额:
    $ 50.71万
  • 项目类别:
Unified Program for Therapeutics in Children (UPTiC)
儿童治疗统一计划 (UPTiC)
  • 批准号:
    10676078
  • 财政年份:
    2019
  • 资助金额:
    $ 50.71万
  • 项目类别:
Chromatin maintenance in cancer progression
癌症进展中的染色质维持
  • 批准号:
    9248144
  • 财政年份:
    2015
  • 资助金额:
    $ 50.71万
  • 项目类别:
Chromatin maintenance in cancer progression
癌症进展中的染色质维持
  • 批准号:
    9150499
  • 财政年份:
    2015
  • 资助金额:
    $ 50.71万
  • 项目类别:
Chromatin maintenance in cancer progression
癌症进展中的染色质维持
  • 批准号:
    9751217
  • 财政年份:
    2015
  • 资助金额:
    $ 50.71万
  • 项目类别:

相似海外基金

Pulmonary Hypertension: State of the Art and Therapeutic Opportunities
肺动脉高压:最新技术和治疗机会
  • 批准号:
    10682118
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Dysregulation of inflammation resolution as therapeutic target for IBD
炎症消退失调作为 IBD 的治疗靶点
  • 批准号:
    10663586
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular
缓释 PNA5 的 GMP 生产和 IND 启用研究:一种治疗阿尔茨海默氏病相关痴呆和血管性认知障碍患者认知障碍的新疗法
  • 批准号:
    10819329
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
一流的牛皮癣局部免疫调节疗法
  • 批准号:
    10820331
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
弥漫性大B细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    10737214
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
晚期前列腺癌中 Trop-2 的分子调控和表达:确定最佳治疗领域
  • 批准号:
    10735996
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
CD206 TAM 的治疗靶向增强转移性去势抵抗性前列腺癌的适应性和先天抗肿瘤免疫反应
  • 批准号:
    10731906
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Development of a digital therapeutic targeting anxiety sensitivity to reduce PTSD-SUD in women presenting for emergency care after sexual assault.
开发一种针对焦虑敏感性的数字疗法,以减少性侵犯后寻求紧急护理的女性的 PTSD-SUD。
  • 批准号:
    10449766
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
Novel therapeutic intervention of early-stage T1D
早期 T1D 的新型治疗干预
  • 批准号:
    10698534
  • 财政年份:
    2023
  • 资助金额:
    $ 50.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了